Could CBD soon be legally sold as a dietary supplement or food in the US? The answer depends on how quickly the federal regulatory framework on cannabis in general and CBD in particular can be eased – and that’s in some doubt, according to experts contacted by CBD-Intel.

The details of regulation are likely to depend on the type of cannabinoid product, the source, how the product will be used, potency and drug-to-drug interactions.

Former FDA commissioner Scott Gottlieb said it could take two to three years, before stepping down earlier this month. That now appears to be a best case scenario.

Read full article
I'm already a subscriber
Author default picture


This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization